

# RECORD OF TELEPHONE CONVERSATION

## Submission Information

<b>Application Type</b>	BLA
<b>STN</b>	125614/0.0
<b>Review Office</b>	OVRR
<b>Applicant</b>	GlaxoSmithKline Biologicals / Lic. # 1617
<b>Product</b>	Zoster Vaccine Recombinant, Adjuvanted

## Telecon Details

<b>Telecon Date/Time</b>	18-APR-2017 01:30 PM
<b>Author</b>	NAIK, RAMACHANDRA
<b>FDA Originated?</b>	Yes
<b>Communication Categories</b>	IR - Information Request
<b>Telecon Summary</b>	Statistical IR regarding secondary efficacy endpoint analyses and SAS codes
<b>FDA Participants</b>	Ramachandra Naik, Michael Smith and Carmen Collazo-Custodio
<b>Applicant Participants</b>	Jody Gould and Norris Pyle

**Telecon Body:** E-mail message and the IR attachment pasted below.

## RECORD OF TELEPHONE CONVERSATION

**From:** Naik, Ramachandra  
**Sent:** Tuesday, April 18, 2017 1:30 PM  
**To:** 'Jody Gould'  
**Cc:** Norris Pyle; Smith, Michael (CBER); Collazo, Carmen  
**Subject:** STN 125614/0: Statistical IR

Dear Dr. Gould,

Attached is a request for additional statistical information regarding STN 125614/0 (Zoster Vaccine Recombinant, Adjuvanted). Please provide your responses, in an amendment to STN 125614/0, by Friday, May 5, 2017.

Please confirm receipt of this message, and let us know if you have any questions or need additional information.

Regards,  
Ram

**Ramachandra S Naik, Ph.D.**  
Primary Reviewer/Regulatory Project Manager  
Food and Drug Administration  
CBER/OVRR/DVRPA/RRB3  
10903 New Hampshire Avenue  
Building 71, Room 3045  
Silver Spring, MD 20993  
Phone: (301) 796-2640  
FAX: (301) 595-1244

**THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.**

# **RECORD OF TELEPHONE CONVERSATION**

## **CENTER FOR BIOLOGICS EVALUATION AND RESEARCH OFFICE OF VACCINES RESEARCH AND REVIEW DIVISION OF VACCINES AND RELATED PRODUCT APPLICATIONS**

**Date:** April 18, 2017

**Pages:** 2

**To:** Jody Gould, Ph.D.  
Senior Director  
North American Regulatory Affairs, Vaccines  
GlaxoSmithKline Biologicals  
14200 Shady Grove Road  
VR1500  
Rockville, MD 20850  
Telephone: (610) 917-2985 Fax: (240) 238-9822

**From:** Division of Vaccines and Related Products Applications  
Office of Vaccines Research and Review  
Point of Contact: Ramachandra Naik, Ph.D.  
Regulatory Project Manager  
10903 New Hampshire Ave., White Oak Bldg. 71  
Silver Spring, MD 2993-0002  
Telephone: (301)-796-2640 Fax: (301)-595-1124

**STN:** 125614/0

**Product:** Shingrix (Zoster Vaccine Recombinant, Adjuvanted)

**Subject:** Request for additional information

Dear Dr. Gould,

Our review of the information provided in your BLA dated October 21, 2016, for Zoster Vaccine Recombinant, Adjuvanted, is ongoing. We have the following comments and requests for additional information:

1. Regarding the evaluation of Vaccine Efficacy (VE) in the reduction in use of pain medications for studies Zoster-006 and Zoster-022, you changed the analysis method from what was specified in the protocol. You stated that a more adapted method (i.e., binomial test instead of Poisson procedure) was used. Please explain what you mean by "more adapted" and provide the VE analysis results in modified Total Vaccinated Cohort (mTVC) using the protocol-specified method, i.e., generating a table similar to Table 7.26 in the CSR of study Zoster-006 and a table similar to Table 7.19 in the CSR of study Zoster-022 using the Poisson procedure.

## **RECORD OF TELEPHONE CONVERSATION**

2. Regarding the evaluation of VE in the prevention of overall Postherpetic Neuralgia (PHN) for study Zoster-006, please clarify what statistical method was used to calculate the confidence intervals for the VE estimates. It appears that when the number of cases in the vaccine group is zero, the exact Poisson method reports a median unbiased estimate instead of a conditional maximum likelihood estimate. In addition, please also provide the SAS codes you used to compute the confidence intervals as you presented in Table 34 in the CSR of study Zoster-006.

Please provide your responses, in an Amendment to STN 125614/0, by Friday, May 5, 2017. We recommend that you restate each item and follow it with your explanation or clarification. Use of this format helps organize the relevant information and provides a self-contained document that facilitates future reference. If you have any questions about this communication, please contact Ramachandra Naik, Ph.D. or Michael Smith, Ph.D. at (301) 796-2640.